Abstract
Bone is a very active tissue that is constantly remodeled in order to adapt to mechanic or metabolic requirements. Since disturbances in bone remodeling may result in relevant skeletal diseases, there is great interest in tools to assess bone remodeling for scientific and clinical applications. Bone turnover markers (BTMs) are among these tools; this chapter presents established markers of bone resorption and bone formation and also selected novel markers. For each marker the biochemical background will be described; in addition you will learn about non-pathological and pathological conditions that lead to alterations of the levels of BTMs. Finally, strengths and weaknesses of the BTMs – especially with regard to their potential clinical applications – will be discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Johansson H, Oden A, Kanis JA, et al. A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int. 2014;94:560–7.
Vasikaran S, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391–420.
Vasikaran S, et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory medicine. Position on bone markers standards in osteoporosis. Clin Chem Lab Med. 2011;49:1271–4.
Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaissè JM. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res. 2003;18:859–67.
Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Vaananen HK. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab. 2006;52:499–509.
Fahrleitner-Pammer A, Herberth J, Browning SR, Obermayer-Pietsch B, Wirnsberger G, Holzer H, Dobnig H, Malluche HH. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res. 2008;23:1850–8.
Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay for the carboxyterminal propeptide of human type I procollagen (PICP). Clin Chem. 1990;36:1328–32.
Melkko J, et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem. 1996;42:947–54.
Vergnaud P, et al. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women; the EPIDOS study. J Clin Endocrinol Metab. 1997;82:719–24.
Pietschmann P, Skalicky M, Kneissel M, Rauner M, Hofbauer G, Stupphann D, Viidik A. Bone structure and metabolism in a rodent model of male senile osteoporosis. Exp Gerontol. 2007;42:1099–108.
Sipos W, Zysset P, Kostenuik P, Mayrhofer E, Bogdan C, Rauner M, Stolina M, Dwyer D, Sommerfeld-Stur I, Pendl G, Resch H, Dall’Ara E, Varga P, Pietschmann P. OPG-Fc treatment in growing pigs leads to rapid reduction in bone resorption markers, serum calcium, and bone formation markers. Horm Metab Res. 2011;43:944–9.
Rauner M, Föger-Samwald U, Kurz MF, Brünner-Kubath C, Schamall D, Kapfenberger A, Varga P, Kudlacek S, Wutzl A, Höger H, Zysset PK, Shi GP, Hofbauer LC, Sipos W, Pietschmann P. Cathepsin S controls adipocytic and osteoblastic differentiation, bone turnover, and bone microarchitecture. Bone. 2014;64:281–7.
Garnero P. New developments in biological markers of bone metabolism. Bone. 2014;66:46–55.
Bonnet N, Garnero P, Ferrari S. Periostin action in bone. Mol Cell Endocrinol. 2016;432:75–82.
Merle B, Garnero P. The multiple facets of periostin in bone metabolism. Osteoporos Int. 2012;23:1199–212.
Rousseau JC, Sornay-Rendu E, Bertholon C, Chapurlat R, Garnero P. Serum periostin is associated with fracture risk in postmenopausal women: a 7 years prospective analysis of the OFELY study. J Clin Endocrinol Metab. 2014;99:2533–9.
Kerschan-Schindl K, Ebenbichler G, Gruther W, Petrikic A, Föger-Samwald U, Kudlacek S, Patsch J, Jaksch P, Klepetko W, Pietschmann P. Serum levels of musculoskeletal markers of lung transplantation recipients (manuscript in preparation).
Murali SK, Roschger P, Zeitz U, Klaushofer K, Andrukhova O, Erben RG. FGF23 regulates bone mineralization in a 1,25(OH)2 D3 and Klotho-independent manner. J Bone Miner Res. 2016;31(1):129–42.
Lian JB, Stein HS, van Wijnen AJ, Stein JL, Hassan MQ, Gaur T, et al. Micro RNA control of bone formation and homeostasis. Nat Rev Endocrinol. 2012;8:212–7.
Sugatani T, Hruska KA. Impaired micro-RNA pathways diminish osteoclast differentiation and function. J Biol Chem. 2009;284:4667–78.
Weilner S, Schraml E, Wieser M, Messner P, Schneider K, Wasermann K, Micutkova L, Fortschegger K, Maier AB, Westendorp R, Resch H, Wolbank S, Redl H, Jamsen-Dürr P, Pietschmann P, Grillari-Voglauer R, Grillari J. Secreted microvascular miR-31 inhibits osteogenic differentiation of mesenchymal stem cells. Aging Cell. 2016;15:744–54.
Weilner S, Skalicky S, Salzer B, Keider V, Wagner M, Hildner F, Gabriel C, Dovjak P, Pietschmann P, Grillari-Voglauer R, Grillari J, Hackl M. Differentially circulating miRNAs after recent osteoporotic fractures can influence osteogenic differentiation. Bone. 2015;79:43–51.
Michelsen J, Wallaschofski H, Friedrich N, Spelhagen C, Rettig R, Ittermann T, Nauck M, Hannemann A. Reference intervals for serum concentrations of three bone turnover markers for men and women. Bone. 2013;57:399–404.
Kerschan-Schindl K, Thalmann M, Sodeck GH, Skenderi K, Matalas AL, Grampp S, Ebner C, Pietschmann P. A 246-km continuous running race causes significant changes in bone metabolism. Bone. 2009;45:1079–83.
Kerschan-Schindl K, Thalmann M, Weiss E, Tsironi M, Föger-Samwald U, Meinhart J, Skenderi K, Pietschmann P. Changes in serum levels of myokines and Wnt-antagonists after and ultramarathon race. PLoS One. 2015;10:e0132478.
Lombardi G, Sanchis-Gomar F, Perego S, Sansoni V, Banfi G. Implications of exercise-induced adipo-myokines in bone metabolism. Endocrine. 2016;54:284–305.
Cavalier E, Bergmann P, Bruyere O, Delanaye P, Durnez A, Devogelaer JP, Ferrari SL, Gielen E, Goemare S, Kaufmann JM, Nzeusseu Toukap A, Reginster JY, Rousseau AF, Rozenberg S, Scheen AJ, Body JJ. The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. Osteoporos Int. 2016;27:2181–95.
Bergmann P, Body JJ, Boonen S, et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract. 2009;63:19–26.
Bandeira F, Costa AG, Filho MAS, Pimentel L, Lima L, Bilezikian JP. Bone markers and osteoporosis therapy. Arq Bras Endocrinol Metab. 2014;58:504–13.
Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004;19:1259–69.
Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J, Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222–9.
Glover S, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J, Belleli R, Wright TM, John MR. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone. 2009;45:1053–8.
Bouxsein ML, Delmas PD. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res. 2008;23:1155–67.
Kerschan-Schindl K, Mikosch P, Obermayer-Pietsch B, Gasser RW, Dimai HP, Fahrleitner-Pammer A, Dobnig H, Roschger P, Preisinger E, Klaushofer K, Resch H, Pietschmann P. Current controversies in clinical management of postmenopausal osteoporosis. Exp Clin Endocrinol Diabetes. 2014;122:437–44.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Kerschan-Schindl, K., Föger-Samwald, U., Pietschmann, P. (2017). Bone Turnover Markers. In: Pietschmann, P. (eds) Principles of Bone and Joint Research. Learning Materials in Biosciences. Springer, Cham. https://doi.org/10.1007/978-3-319-58955-8_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-58955-8_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-58954-1
Online ISBN: 978-3-319-58955-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)